Juno Therapeutics Inc (NASDAQ: JUNO)
Juno Therapeutics is having a relatively strong day in the market today. When the opening bell rang, the stock was already well into the green, where it has stayed throughout the session thus far. However, with a bit of news that’s coming down the wire at the moment, we believe the thing could soar. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to JUNO ahead.
What We’re Seeing From JUNO
As mentioned above, Juno Therapeutics is having a relatively strong day in the market today. On the opening bell, the stock found itself well into the green. Throughout the trading session, it has maintained gains. At the moment (1:01), JUNO is trading at $21.10 per share after a gain of $0.67 per share or 3.28% thus far today.
Why The Stock Is Up
The gains on JUNO had to do with a presentation that was planned with regard to data from the TRANSCEND study. However, now that the data has been presented, we’re expecting that we could see larger gains. After all, the data that was presented was overwhelmingly positive.
First and foremost, Juno Therapeutics said that the study achieved a 60% Complete Response Rate in patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma. On top of the strong Complete Response Rate, there were no severe CRS reported nor any deaths reported during the trial.
What We’ll Be Watching For Ahead
Obviously, the CNA Finance team will be keeping a close eye on JUNO ahead following such strong news. In particular, we’re looking forward to hear more about the company’s plans now that they have this data; what the next steps may be. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikipedia]